TCRX Company Profile and Key Details

Q: Who are the executives of TCRX?

Dr. Zoran Zdraveski J.D., Ph.D.Chief Legal Officer & Company Sec.Mr. David P. SouthwellPres, Chief Executive Officer & DirectorMs. Heather SavelleVice President of Investor RelationsMr. Brian Michael Silver J.D.Senior Vice President, Chief Financial Officer & TreasurerMr. Tomasz Kula Ph.D.Co-Founder & Member of Advisory BoardMr. Ray LockardSenior Vice President of Technical Operations & QualityMs. Ann HargravesSenior Vice President of HRDr. Shrikanta Chattopadhyay M.D.Senior Vice President of Medical & Translational MedicineDr. Debora Barton M.D.Chief Medical OfficerDr. Stephen J. Elledge Ph.D.Co-Founder & Chairman of Scientific Advisory BoardDr. Gavin MacBeath Ph.D.Chief Executive Officer, Director & Interim Principal Financial OfficerMr. Leiden DworakPrincipal Accounting OfficerDr. William Desmarais M.B.A., Ph.D.Chief Bus. Officer

NASDAQ : TCRX

TScan Therapeutics

$0.31

-0.0216-6.48%

At Close 4:00 PM

$0.33

+0.0194+6.22%

After-Market 08:30 PM

57.22

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

TScan Therapeutics, Inc. (TCRX) stock declined over -6.48%, trading at $0.31 on NASDAQ, down from the previous close of $0.33. The stock opened at $0.34, fluctuating between $0.31 and $0.36 in the recent session.

Stock Snapshot

0.3335

Prev. Close

19.05M

Market Cap

0.3096

Day Low

-0.34

P/E Ratio

-0.91

EPS (TTM)

-0.98

Cash Flow per Share

0.34

Open

61.07M

Number of Shares

0.3571

Day High

83.56%

Free Float in %

2.3

Book Value

1.14M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 18, 2026	0.34	0.36	0.31	0.31	1.14M
Sep 17, 2026	0.34	0.36	0.32	0.33	1.1M
Sep 16, 2026	0.33	0.34	0.32	0.33	883.85K
Sep 15, 2026	0.32	0.32	0.29	0.32	677.25K
Sep 14, 2026	0.32	0.33	0.31	0.31	1.1M
Sep 11, 2026	0.32	0.33	0.31	0.32	873.12K
Sep 10, 2026	0.32	0.35	0.31	0.32	804.59K
Sep 09, 2026	0.34	0.34	0.33	0.33	704.25K
Sep 08, 2026	0.38	0.38	0.33	0.34	1.54M
Sep 04, 2026	0.37	0.42	0.36	0.39	1.65M
Sep 03, 2026	0.38	0.40	0.35	0.37	3.09M
Sep 02, 2026	0.55	0.57	0.36	0.38	8.42M
Sep 01, 2026	0.72	0.77	0.66	0.67	819.8K
Aug 31, 2026	0.75	0.77	0.72	0.73	330.05K
Aug 28, 2026	0.76	0.78	0.75	0.75	150.69K
Aug 27, 2026	0.78	0.80	0.75	0.75	287.5K
Aug 26, 2026	0.78	0.79	0.77	0.78	68.35K
Aug 25, 2026	0.79	0.81	0.78	0.79	180.6K
Aug 24, 2026	0.79	0.80	0.77	0.80	194.41K
Aug 21, 2026	0.79	0.79	0.77	0.78	136.15K

Contact Details

Waltham, MA 02451

United States

https://www.tscan.com 857 399 9500

About Company

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Stock Peers

ARGX

-5.45-0.55%

argenx SE$990.32 REGN

-4.6-0.58%

Regeneron Pharmaceuticals, Inc.$784.85 MDGL

-2.88-0.54%

Madrigal Pharmaceuticals, Inc.$531.52 VRTX

-8.00008-1.55%

Vertex Pharmaceuticals Incorporated$508.34 UTHR

-2.64-0.53%

United Therapeutics Corporation$494.63 ONC

-2.62-0.74%

BeOne Medicines AG$350.84 KRYS

-2.08-0.61%

Krystal Biotech, Inc.$336.67 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-11.52-3.71%

Praxis Precision Medicines, Inc.$298.95 LGND

-1.21-0.43%

Ligand Pharmaceuticals Incorporated$283.49

Frequently Asked Questions

What is the current TScan Therapeutics, Inc. (TCRX) stock price?

TScan Therapeutics, Inc. (NASDAQ: TCRX) stock price is $0.31 in the last trading session. During the trading session, TCRX stock reached the peak price of $0.36 while $0.31 was the lowest point it dropped to. The percentage change in TCRX stock occurred in the recent session was -6.48% while the dollar amount for the price change in TCRX stock was - $0.02.

TCRX's industry and sector of operation?

The NASDAQ listed TCRX is part of Biotechnology industry that operates in the broader Healthcare sector. TScan Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of TCRX?

Dr. Zoran Zdraveski J.D., Ph.D.
Chief Legal Officer & Company Sec.
Mr. David P. Southwell
Pres, Chief Executive Officer & Director
Ms. Heather Savelle
Vice President of Investor Relations
Mr. Brian Michael Silver J.D.
Senior Vice President, Chief Financial Officer & Treasurer
Mr. Tomasz Kula Ph.D.
Co-Founder & Member of Advisory Board
Mr. Ray Lockard
Senior Vice President of Technical Operations & Quality
Ms. Ann Hargraves
Senior Vice President of HR
Dr. Shrikanta Chattopadhyay M.D.
Senior Vice President of Medical & Translational Medicine
Dr. Debora Barton M.D.
Chief Medical Officer
Dr. Stephen J. Elledge Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Dr. Gavin MacBeath Ph.D.
Chief Executive Officer, Director & Interim Principal Financial Officer
Mr. Leiden Dworak
Principal Accounting Officer
Dr. William Desmarais M.B.A., Ph.D.
Chief Bus. Officer

How TCRX did perform over past 52-week?

TCRX's closing price is 7.55% higher than its 52-week low of $0.29 where as its distance from 52-week high of $2.57 is -87.86%.

How many employees does TCRX have?

Number of TCRX employees currently stands at 138.

Link for TCRX official website?

Official Website of TCRX is: https://www.tscan.com

How do I contact TCRX?

TCRX could be contacted at phone 857 399 9500 and can also be accessed through its website. TCRX operates from 830 Winter Street, Waltham, MA 02451, United States.

How many shares of TCRX are traded daily?

TCRX stock volume for the day was 1.14M shares. The average number of TCRX shares traded daily for last 3 months was 862.11K.

What is the market cap of TCRX currently?

The market value of TCRX currently stands at $19.05M with its latest stock price at $0.31 and 61.07M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	138
Beta	1.07
Sales or Revenue	$21.05M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	138
Beta	1.07
Sales or Revenue	$21.05M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

TCRX Company Profile and Key Details

TScan Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways